. 2012 Jul 31;2012:732027. doi: 10.1155/2012/732027

Table 2.

Univariate and multivariate analyses according to overall survival.

Variable	Overall survival (median, months)	P	HR (95% CI)	P
Age (years)			1.2	0.303
Age < 49	26	0.301	(0.8–1.9)
Age 49	26	0.301	(0.8–1.9)

Tumor stage				<0.001
1-2	38	<0.001	2.7 (1.7–4.4)
3-4	17	<0.001	2.7 (1.7–4.4)

Nodes				0.091
Negative	38	0.276	0.6 (0.4–1.1)
Positive	24	0.276	0.6 (0.4–1.1)

Grade				0.083
1-2	39	0.004	1.5 (0.9–2.2)
3	20	0.004	1.5 (0.9–2.2)

Hormone receptor				0.003
Positive	37	<0.001	0.2 (0.1–0.6)
Negative	18	<0.001	0.2 (0.1–0.6)

HER2				0.015
Positive	26	0.824	0.3 (0.1–0.8)
Negative	24	0.824	0.3 (0.1–0.8)

Triple-negative				0.072
Positive	15	0.005	0.4 (0.1–1.1)
Negative	31	0.005	0.4 (0.1–1.1)

Metastatic site				0.047
Single	38	0.018	1.6 (1.0–2.4)
Multiple	24	0.018	1.6 (1.0–2.4)

Type of metastases				0.042
Nonvisceral	38	0.019	1.6 (1.0–2.5)
Visceral	23	0.019	1.6 (1.0–2.5)

Overweight or obesity at recurrence				0.680
Yes	31	0.310	0.9 (0.6–1.4)
No	23	0.310	0.9 (0.6–1.4)

Diabetes at recurrence				0.709
No	26	0.227	0.9 (0.4–1.9)
Yes	18	0.227	0.9 (0.4–1.9)

Mean glucose >130				0.034
No	27	0.023	2.8 (1.1–7.3)
Yes	12	0.023	2.8 (1.1–7.3)

HR: Hazard ratio.